Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer

J Surg Oncol. 2007 Dec 1;96(7):605-10. doi: 10.1002/jso.20716.

Abstract

Background and objectives: Vascular endothelial growth factor (VEGF) is known as an important factor in the growth and metastasis of cancer cells. In 2001, a novel angiogenesis factor, endocrine gland-derived vascular endothelial growth factor (EG-VEGF), was cloned. In this study, we investigated the expression of EG-VEGF in colorectal cancer, the relationship between its expression and clinicopathological factors, and the in vitro activity of EG-VEGF transfectants.

Methods: We determined expression levels of EG-VEGF in 113 advanced colorectal cancers resected in our hospital by quantitative PCR, and compared the expression levels and clinicopathological findings by multivariate analyses.

Results: The expression of EG-VEGF mRNA was positive in 31 cancers and negative in 82 cancers. We found that compared with the negative expression of the EG-VEGF gene, its positive expression was more frequently associated with hematogenous metastasis, and was associated with a poorer survival rate. In addition, EG-VEGF transfectants showed a higher degree of in vitro tubular formation than control cells.

Conclusions: We speculate that, in colorectal cancers, the EG-VEGF gene functions as an important factor in angiogenesis in primary and metastatic lesions, and consider that it is useful as a novel prognostic factor. EG-VEGF molecule-targeted therapy has the potential for improving survival rates.

MeSH terms

  • Cell Line, Tumor
  • Colorectal Neoplasms / metabolism*
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology
  • Humans
  • Lymphatic Metastasis
  • Prognosis
  • RNA, Messenger / analysis
  • Risk Factors
  • Survival Rate
  • Vascular Endothelial Growth Factor, Endocrine-Gland-Derived / genetics*

Substances

  • RNA, Messenger
  • Vascular Endothelial Growth Factor, Endocrine-Gland-Derived